Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists
- 17 June 2009
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (16) , 4777-4780
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A Structural and in Vitro Characterization of Asoprisnil: A Selective Progesterone Receptor ModulatorMolecular Endocrinology, 2007
- Emerging drugs in endometriosisExpert Opinion on Emerging Drugs, 2006
- Progesterone Receptor Ligand Binding Pocket Flexibility: Crystal Structures of the Norethindrone and Mometasone Furoate ComplexesJournal of Medicinal Chemistry, 2004
- Stromal Cell-Derived Factor 1, a Novel Target of Estrogen Receptor Action, Mediates the Mitogenic Effects of Estradiol in Ovarian and Breast Cancer CellsMolecular Endocrinology, 2003
- Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestoneThe Journal of Steroid Biochemistry and Molecular Biology, 2001
- Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonistThe EMBO Journal, 1999
- Hormone-Dependent Coactivator Binding to a Hydrophobic Cleft on Nuclear ReceptorsScience, 1998
- Atomic structure of progesterone complexed with its receptorNature, 1998
- Nonsteroidal human progesterone receptor modulators from the marine alga Cymopolia barbata.Molecular Pharmacology, 1995
- Progestin Regulation of Cellular Proliferation*Endocrine Reviews, 1990